Subanaesthetic intravenous ketamine has been shown to be as effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic, treatment-resistant depression.
As the mental health crisis continues to escalate, those suffering from mental health issues are seeking new solutions to combat PTSD, depression, anxiety, trauma and other...
Awakn Life Sciences and the University of Exeter (UoE) are collaborating to put in place a framework for a Phase 3 trial exploring the use of...
Breaking Convention 2023 will see a panel of experts join together to discuss the benefits and risks of ketamine-assisted psychotherapy as the treatment begins to gain...
In this article, Nina Patrick, Ph.D.,
By combining AI, clinical testing and computer analysis of vast amounts of biomedical knowledge and electronic health records, researchers at Case Western Reserve University have found...
Awakn Life Sciences has announced that Awakn Clinics Trondheim is now open and that it has initiated a feasibility study of MDMA leveraging Catalent’s proprietary Zydis...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Awakn Life Sciences an Innovation Passport for its proprietary ketamine-assisted therapy for the treatment of...
Researchers at the University of Alabama, Birmingham, say the study findings demonstrate the critical role of the protein Tiam1 in the pathophysiology of chronic pain-induced mood...
Awakn Life Sciences has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine and an optimised route...
